Empresa Saniona AB Nasdaq Stockholm
Acciones
SE0005794617
Biotecnología e investigación médica
Resumen de negocios
Ventas por actividad
SEK en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Rare Diesease Patients Innovative Treatments
100,0
%
| 15 | 100,0 % | 17 | 100,0 % | +10,19 % |
Ventas por región
SEK en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Germany
51,8
%
| - | - | 9 | 51,8 % | - |
United Kingdom
44,5
%
| - | - | 7 | 44,5 % | - |
Denmark
3,8
%
| - | - | 1 | 3,8 % | - |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Founder | 66 | 01/01/11 | |
Thomas Feldthus
CEO | Chief Executive Officer | 64 | 01/01/11 |
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Anita Milland
DFI | Director of Finance/CFO | 56 | 01/01/14 |
Karin Nielsen
CTO | Chief Tech/Sci/R&D Officer | 54 | - |
Chief Tech/Sci/R&D Officer | 65 | 01/05/20 | |
Corporate Officer/Principal | 52 | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Jørgen Drejer
FOU | Founder | 69 | 01/01/11 |
Director/Board Member | 66 | 01/01/15 | |
Anna Ljung
BRD | Director/Board Member | 44 | 19/01/18 |
Director/Board Member | 58 | 01/01/23 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 132 529 086 | 80 887 377 ( 61,03 %) | 0 | 61,03 % |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Saniona A/S
Saniona A/S Miscellaneous Commercial ServicesCommercial Services Part of Saniona AB, Saniona A/S is a Danish company dedicated to improving the lives of rare disease patients worldwide through scientific innovation. The company focuses on Prader-Willi Syndrome, a rare genetic disorder characterized by insatiable appetite, abnormal growth and body composition, low muscle tone, and social/emotional/cognitive deficits. Saniona is a leader in the discovery of highly specific ion channel modulators, which is a validated approach to treating diseases such as diabetes, hypertension, and epilepsy. The company's robust ion channel drug discovery engine has led to the development of San711, a first-in-class positive allosteric modulator of GABAA ?3 receptors, and San903, a potential first-in-class inhibitor of the calcium-activated potassium ion channel, KCA3.1, both of which are in development for rare neuropathic, inflammatory, and fibrotic disorders. |
Miscellaneous Commercial Services
|
Sector
Ventas por región
Varia. 1 de ene. | Capi. | |
---|---|---|
+9,58 % | 115 mil M | |
+12,41 % | 106 mil M | |
-2,59 % | 21,96 mil M | |
-12,38 % | 21,87 mil M | |
-5,29 % | 19,21 mil M | |
-3,35 % | 18,08 mil M | |
-38,57 % | 17,71 mil M | |
+7,51 % | 14,32 mil M | |
+35,67 % | 12,42 mil M |